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Abstract
Introduction: Dysregulated angiogenesis is implicated in the pathogenesis of rheumatoid arthritis (RA). To provide
a more profound understanding of arthritis-associated angiogenesis, we evaluated the expression of angiogenesis-
modulating genes at onset, peak and declining phases of collagen-induced arthritis (CIA), a well-established mouse
model for RA.
Methods: CIA was induced in DBA/1 mice with type II collagen. Functional capillary density in synovial tissue of
knee joints was determined by intravital fluorescence microscopy. To assess the ability of arthritic joint
homogenates to induce angiogenesis, an endothelial chemotaxis assay and an in vivo matrigel plug assay were
employed. The temporal expression profile of angiogenesis-related genes in arthritic paws was analysed by
quantitative real-time RT-PCR using an angiogenesis focused array as well as gene specific PCR. Finally, we
investigated the therapeutic effect of a monoclonal antibody specifically blocking the binding of VEGF to
neuropilin (NRP)-1.
Results: Although arthritic paw homogenates displayed angiogenic activity in vitro and in vivo, and synovia of
arthritic paws appeared highly vascularised on histological examination, the functional capillary density in arthritic
knee synovia was significantly decreased, whereas capillary diameter was increased. Of the 84 genes analysed,
41 displayed a differential expression in arthritic paws as compared to control paws. Most significant alterations
were seen at the peak of clinical arthritis. Increased mRNA expression could be observed for VEGF receptors (Flt-1,
Flk-1, Nrp-1, Nrp-2), as well as for midkine, hepatocyte growth factor, insulin-like growth factor-1 and angiopoietin-1.
Signalling through NRP-1 accounted in part for the chemotactic activity for endothelial cells observed in arthritic
paw homogenates. Importantly, therapeutic administration of anti-NRP1B antibody significantly reduced disease
severity and progression in CIA mice.
Conclusions: Our findings confirm that the arthritic synovium in murine CIA is a site of active angiogenesis, but an
altered balance in the expression of angiogenic factors seems to favour the formation of non-functional and
dilated capillaries. Furthermore, our results validate NRP-1 as a key player in the pathogenesis of CIA, and support
the VEGF/VEGF receptor pathway as a potential therapeutic target in RA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that
causes chronic inflammation of synovial joints, eventually
resulting in the destruction of cartilage and bone [1].
During RA, the synovial tissue becomes infiltrated by
inflammatory cells and increases greatly in mass due to
the tumour-like proliferation of activated synoviocytes. In
response to the growing metabolic demand caused by
synoviocyte proliferation, blood vessels develop, which
nourish and oxygenate this synovial pannus, promoting it
to invade and degrade adjacent cartilage and bone. Neo-
vessels exacerbate inflammation by further facilitating
the ingress of inflammatory cells and mediators into the
joint [2,3]. Targeting the synovial vasculature has there-
fore been proposed as a possible therapeutic strategy in
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RA, especially since the approval of angiogenesis inhibi-
tors for certain cancers.
In RA, a luxuriant vasculature is an early feature of the
arthritic synovium , and the number of synovial blood
vessels correlates with hyperplasia, mononuclear cell
infiltration and indices of joint tenderness [4]. The vascu-
lar turnover in the arthritic synovium is increased, and
synovial endothelial cells express markers of proliferation
[5]. Although the hyperplasic RA synovium is highly
vascularised, paradoxically the tissue environment is
chronically hypoxic [6]. Synovial fluids from RA joints
have been shown to promote endothelial cell migration
and proliferation, and to induce vessel formation in an
angiogenesis assay [7,8], which reflects an active, pro-
angiogenic phenotype of the arthritic synovium. Indeed,
a number of angiogenic factors, expression of which is
triggered by the hypoxic and inflammatory environment
within the arthritic joint [9,10], are abundant in RA syno-
vial tissue, including vascular endothelial growth factor
(VEGF) [8,11], angiopoietins [10,12], hepatocyte growth
factor (HGF) [13] and fibroblast growth factor (FGF)-2
[14]. Although new vessel formation is a highly coordi-
nated process, VEGF is generally agreed to be a crucial
regulator of angiogenesis in RA [3]. Increased amounts of
VEGF can be detected in the synovial tissue and fluid as
well as in the circulation of RA patients [9,11,15]. Serum
levels of VEGF correlate with markers of inflammation,
disease activity and radiographic progression [15,16].
During RA, VEGF seems to mediate its effects through
its two tyrosine kinase receptors fms-like tyrosine kinase
(FLT)-1 and kinase insert domain receptor (KDR; mouse
homolog is fetal liver kinase (FLK)-1), and neuropilin
(NRP)-1 [11,17].
However, although the importance of angiogenesis in
arthritis progression is well recognized, there is little
information about the function of the synovial vascula-
ture as well as the molecular mechanisms implicated in
arthritis-associated angiogenesis. Furthermore, the con-
comitant presence of hypoxia and angiogenesis is a con-
undrum. The model of collagen-induced arthritis (CIA)
resembles many pathological features of RA, and
although, it does not perfectly duplicate the human dis-
ease, it has helped to validate TNFa as a therapeutic tar-
get for RA [18]. In the mouse model of CIA, extensive
synovial neovascularisation is a prominent histological
feature of arthritic joints [19-21], and disease onset is
associated with a reduction in synovial oxygen tension
[19]. Synovial tissue isolated from arthritic paws of CIA
mice induced a strong angiogenic response in a vascular
window model, which was in part mediated through TIE-
2 receptor signalling [20]. VEGF and its receptors, FLT-1
and FLK-1, are expressed within the inflamed synovial
tissue of CIA joints, and local VEGF levels correlate with
the degree of neovascularisation and disease severity [21].
Further, blocking VEGF function by administration of a
neutralising VEGF antibody [22] or a soluble VEGF
receptor (sFLT-1) [23] to mice with established CIA, sup-
pressed disease progression, whereas exogenous VEGF
exacerbated synovial inflammation and joint destruction
[24].
Based on these observations, we utilised the mouse
CIA model to investigate the functional capillary density
in the inflamed synovium and to analyse genes that are
involved in synovial angiogenesis during arthritis. Gene
expression profiling of murine CIA has been conducted
before [25,26]. However, these reports were based on a
whole genome approach, and many angiogenesis-related
genes, such as VEGF and its receptors, have not been
assessed. Given that relatively little information is avail-
able on the kinetics of angiogenesis-relevant gene
expression in CIA, the present study applied quantitative
reverse transcription (RT)-PCR to investigate the
expression of selected genes at onset, peak and declining
phases of arthritis in DBA/1 mice. The hypoxic micro-
environment in RA, coupled with the paradoxical fea-
ture of increased synovial vascularity, led us to speculate
that the function of the synovial vasculature is disturbed
and that abnormal angiogenic activity might contribute
to the progression of CIA. We thus hypothesised that
angiogenesis-related genes, including growth factors and
receptors, would correlate with arthritis progression and
angiogenic activity, particularly in the established phases
of arthritis, allowing us to identify potential molecular
targets for therapeutic intervention.
Materials and methods
Mice
Male DBA/1J (H-2q) and female C57BL/6 mice were pur-
chased from Harlan Laboratories (Blackthorn, Bicester,
UK) and maintained under standard conditions at the
Biological Services Unit of the Kennedy Institute of
Rheumatology, Imperial College London, UK. Studies
were performed in accordance with the UK Animals
(Scientific Procedures) Act 1986 regulations for the
handling and use of laboratory animals, and followed an
Ethics Committee and Home Office approved project
licence (PPL No: 70/7335 Improving the therapy of rheu-
matoid arthritis). For intravital microscopy studies, male
DBA/1J mice (10 weeks) were obtained from Taconic
(Lille Skensved, Denmark) and kept under standard con-
ditions at the animal care facility of the University of
Rostock, Germany.
Induction and evaluation of arthritis
Type II collagen (CII) was purified from bovine articular
cartilage following the method described by Miller [27].
Prior to usage, CII was dissolved in 0.05M acetic acid.
Complete Freund’s adjuvant (CFA) was prepared by
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grinding 100 mg Mycobacterium tuberculosis (H37Ra;
DIFCO, Becton Dickinson, Oxford, UK) and suspending
it in 30 ml incomplete Freund’s adjuvant (IFA, Becton
Dickinson, Oxford, UK). For the induction of CIA, CII
was emulsified in equal volumes of CFA to prepare a
1 mg/ml solution, and male DBA/1J mice aged 10-12
weeks were injected intradermally at the base of the tail
with 100 μl. Mice were given a booster injection 21 days
post-primary immunisation with 50 µg CII emulsified in
IFA. A control group of mice received injections of CFA
alone followed by IFA alone 21 days later. Following the
boost, mice were examined daily for macroscopic signs
and severity of arthritis. Arthritis severity was recorded
for individual paws using the following scoring system:
0 = normal paw, 1 = mild oedema and/or erythema of
the joint or individual digits; 2 = moderate oedema and
erythema involving the entire paw, 3 = pronounced
oedema and erythema accompanied with joint rigidity.
An arthritis score was assigned to each mouse by sum-
ming up the individual scores, that is, a maximum score
of 12. In conjunction with this, paw swelling was
assessed by measuring the diameter of the hind paws
using POCO 2T callipers (Krœplin Längenmesstechnik,
Schlüchtern, Germany).
Treatment of CIA with anti-NRP1B antibody
Phage-derived monoclonal antibody against neuropilin-1
(anti-NRP1B), which recognises human and mouse
NRP-1, was a kind gift from Genentech, Inc. (South San
Francisco, CA, USA) [28]. To treat CIA, mice were
injected intraperitoneally with 200 µg anti-NRP1B anti-
body (n = 10) or PBS (n = 10) starting on day 1, follow-
ing on day 4, and 7 of arthritis. In a pilot experiment, a
group of mice received 200 µg human IgG1 isotype con-
trol antibody (Eureka, Emeryville, CA, USA). Arthritis
scoring and paw swelling measurement were performed
by an investigator blinded to treatment assignment.
Immunohistological analysis
For immunohistological analysis, hind paws were removed
post-mortem, cut once longitudinally and fixed overnight
in 1% paraformaldehyde at 4°C. After decalcification in
0.3M EDTA for two weeks at room temperature, tissue
was cryo-preserved, cut into sections of 6 µm thickness,
and stained for CD31 according to standard procedures.
Briefly, endogenous peroxidase activity was quenched by
incubation in 0.3% H2O2 in methanol for 20 minutes. The
specimens were blocked for 30 minutes in Tris buffered
saline containing 10% normal rabbit serum (Dako UK Ltd,
Ely, UK), and incubated overnight at 4°C with rat anti-
mouse CD31 antibody (1/400; MEC13.3; Pharmingen,
San Diego, CA, USA). The sections were subsequently
incubated for 35 minutes at room temperature with bioti-
nylated rabbit anti-rat IgG (1/400, Dako, Ely, UK),
followed by 35 minutes at room temperature with avidin-
biotin peroxidase complex and 5 minutes diaminobenzi-
dine according to the manufacturer’s instructions (Vectas-
tain ABC kit and DAB, Vector Laboratories, Burlingame,
CA, USA). Immunostained sections were counterstained
with Harris haematoxylin. As control an isotope matched
rat IgG2a antibody was used (R35-95, Pharmingen, San
Diego, CA, USA), which showed no reactivity on tissue
samples (data not shown). Histological scoring was per-
formed blinded by one of the investigators.
RNA extraction
At different time points during the course of CIA, mice
were sacrificed, and paws were dissected and immediately
flash frozen in liquid nitrogen. Paws were disrupted using
a BioPulveriser® (BioSpec Products, Bartlesville, OK, US)
and homogenised in RLT lysis buffer (Qiagen GmbH, Hil-
den, Germany) using a rotor-stator homogeniser (Ultra-
Turrax T8; IKA Werke, Staufen, Germany). Total RNA
was isolated from paw homogenates by phenol/chloroform
extraction, followed by purification using the QIAamp®
RNA Blood kit (Qiagen GmbH, Hilden, Germany) accord-
ing to manufacturer’s instructions. RNA quality was con-
firmed by spectrophotometry and gel electrophoresis.
Samples were used for real-time RT-PCR or PCR-based
array analysis as appropriate.
Real-time RT-PCR
First strand cDNA was prepared using 500 ng of total
RNA, random hexamer primers (Invitrogen, Renfrew,
UK) and the Moloney murine leukaemia virus (MMLV)
reverse transcriptase (Promega, Southampton, UK)
according to the supplier’s instructions. Real-time RT-
PCR was carried out in a Rotorgene 6000 (Corbett
Research, Sydney, Australia) using SYBR Green Jump-
Start Taq ReadyMix (SigmaAldrich, UK) and cDNA
corresponding to 25 ng RNA. Cycling conditions were
2 minutes initial incubation at 50°C, followed by 5 min-
utes at 95°C and amplification for 40 cycles at 95°C for
15 seconds, 60°C for 30 seconds and 70°C for 40 seconds.
The cycle threshold (Ct) value of each reaction was
determined using Corbett’s Rotor-Gene 6 software. To
confirm primer specificity, amplicon melting curves were
recorded after cycle 40 by heating from 60 to 95°C with a
ramp speed of 0.5°C every second. Gene-specific mouse
cDNA sequences were obtained from GenBank (NCBI),
and primers were designed using the Primer3 design
package hosted by the Whitehead Institute for Biomedi-
cal Research. Primers (Table 1) were designed to lie in
different exons to prevent the amplification of genomic
DNA, and optimised to work at an annealing tempera-
ture of 60°C. Primer amplification efficiencies were veri-
fied by real time RT-PCR on serial dilutions of cDNA
according to Pfaffl [29]. The expression of target genes
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was expressed as mRNA level in fold change relative to
the mRNA level in tissue of control mice after normalis-
ing to the Arp (acidic ribosomal phosphoprotein P0)
gene using the comparative Ct-method (2-ΔΔCT).
Mouse Angiogenesis RT2-Profiler™ PCR Array
The Mouse Angiogenesis RT2-Profiler™ PCR Array
(APM-024; SuperArray Bioscience, Frederick, MD) profiles
the expression of 84 genes involved in angiogenesis as well
as five housekeeping genes (b-actin; glyceraldehyde 3-phos-
phate dehydrogenase, Gapdh; heat shock protein-1b,
Hsp-1; hypoxanthine guanine phosphoribosyl transferase 1,
Hprt-1; and b-glucuronidase, Gusb) by real-time PCR using
the SYBR Green detection method. Therefore, 500 ng of
total RNA was reverse transcribed using the Reaction-
Ready™ First Strand cDNA Synthesis Kit (SABioscience,
Frederick, MD, USA) following manufacturer’s instruc-
tions. The generated cDNA was diluted with an appropri-
ate volume of instrument-specific 2x SuperArray RT2
Real-Time™ SYBR Green PCR Master Mix (PA-012) and
ultra pure water, and 25 µl of this reaction mix was added
to each well of the PCR array. The real-time PCR reaction
was performed in an ABI 7700 thermocycler applying the
following program: 2 minutes at 50°C, 10 minutes at 95°C
and 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.
The ABI PRISM® 7700 Sequence Detection System was
used to calculate the Ct value for each well. Data were nor-
malised to four housekeeping genes and analysed by the
comparative Ct-method (2-ΔΔCT).
Preparation of paw homogenates
Mouse paws were skinned, snap frozen, pulverised, and
homogenised in 1.5 ml ice-cold sterile PBS containing
protease inhibitor cocktail (Roche Diagnostics, Burgess
Hill, UK). Debris were removed by centrifugation at 4°C
13.000 rpm for 15 minutes and the supernatants were
filtered using a 0.2 µm sterile syringe filter (Corning
Incorporated, New York, USA). The protein content of
the homogenates was determined using the Pierce BCA
protein assay kit (Pierce, Rockford, IL, USA) following
manufacturer’s guidelines.
Endothelial cell migration assay
Human microvascular endothelial cells (HMEC-1;
gifted from Centers for Disease Control and Preven-
tion, USA) were cultured in MCDB131 medium
(Gibco, Invitrogen, Paisley, UK) containing 10% foetal
calf serum (FCS; Biowest, Nuaillé, France), 100U/ml
penicillin and 0.1 mg/ml streptomycin (PAA, Yeovil,
UK) and 10 ng/ml human epidermal cell growth factor
(PeproTech, London, UK) using gelatine-coated tissue
culture flasks.
Migration of HMEC-1 in response to angiogenic sti-
muli was analysed using a modified Boyden chamber
assay. Briefly, cell culture inserts (8.0 μm pore size; BD
Biosciences, Oxford, UK) were placed into a 24-well plate
and coated with gelatin. Recombinant human VEGF165
(20 ng/ml) or paw homogenates (100 ng/ml), prepared in
MCDB131 medium containing 0.1% FCS were added to
the lower wells. Prior to experiments, HMEC-1 were cul-
tured overnight in 2% FCS MCDB131 medium. 100,000
cells in 200 μl of 0.1% FCS MCDB131 medium were
added to the upper chambers and allowed to migrate for
5 hours at 37°C. After the migration period, cells were
fixed with ice cold 70% ethanol for 10 minutes, treated
with 0.1% TritonX-100 in PBS for 2 minutes and stained
Table 1 Primers applied in this study
Gene Sense primer5’-3’ Antisense primer 5’-3’ Size (bp) Reference
Arp AATCTCCAGAGGCACCATTG TTCAGCGTGTTCAGCAGTG 101 NM_007475
Flt-1 CGGCAGACCAATACAATCCT CCGCTGCCTTATAGATGCTC 174 NM_010228
Flk-1/Kdr CATGCACAGTCTACGCCAAC CCTCCACGTGTCTCCATTCT 126 NM_010612
Hgf GGCCATGGTGCTACACTCTT CTTCTCCTTGGCCTTGAATG 132 NM_010427
Igf-1 TGGATGCTCTTCAGTTCGTG GCAACACTCATCCACAATGC 113 NM_010512
Il-1b CAGGCAGGCAGTATCACTCA ATGAGTCACAGAGGATGGGC 140 NM_008361
Il-6 TACCACTCCCAACAGACCTGTC CTGCAAGTGCATCATCGTTGTTC 140 NM_031168
Mdk CCTGCAACTGGAAGAAGGAA GAGGTGCAGGGCTTAGTCAC 166 NM_010784
Nrp-1 GGAGCTACTGGGCTGTGAAG CCTCCTGTGAGCTGGAAGTC 134 NM_008737
Plgf TGCTGGGAACAACTCAACAG GGACACAGGACGGACTGAAT 146 NM_008827
Tnf GACCCTCACACTCAGATCATC CGCTGGCTCAGCCACTCCAGC 105 NM_013693
Vegf120 GGCTGCTGTAACGATGAAGC GGCTTGTCACATTTTTCTGGC 184 NM_001025257
Vegf164 GGCTGCTGTAACGATGAAGC GGCTCACAGTGATTTTCTGGC 184 NM_009505
Vefg188 GGCTGCTGTAACGATGAAGC CTCACAGTGAACGCTCCAG 255 NM_001025250
Sequences represent primer pairs that were designed using Primer3 design package hosted by the Whitehead Institute for Biomedical Research [55]. References
present Genbank accession numbers for each gene. All primer pairs were designed to span an intron to exclude potential genomic DNA contamination. (Arp:
acidic ribosomal phosphoprotein P0; Flk-1: fetal liver kinase 1; Flt-1: fms-related tyrosine kinase 1; Hgf: hepatocyte growth factor; Igf-1: insulin-like growth factor;
Il: interleukin; Mdk: midkine; Plgf: placental growth factor; Vegf: vascular endothelial growth factor)
Raatz et al. Arthritis Research & Therapy 2012, 14:R169
http://arthritis-research.com/content/14/4/R169
Page 4 of 18
with haematoxylin for 10 minutes. Non-migrated cells
were gently removed from the upper membrane surface
using a cotton swab. Chemotaxis was quantified by
counting nuclei in three random high power fields (HPF,
200×)/well. Each sample was assayed in triplicate.
In vivo Matrigel plug assay
For this assay, 400 µl of ice-cold growth factor-reduced
Matrigel (Becton-Dickinson, Bedford, MA, USA) were
combined with 120 µg/ml paw homogenate, and injected
subcutaneously into the back of female C57BL/6 mice
(aged 7 weeks). Mice simultaneously received a plug con-
taining either homogenate from a healthy or an arthritic
paw. Seven days post-implantation, mice were sacrificed
and plugs carefully dissected, photographed and weighted.
To determine the angiogenic response, the haemoglobin
content in the plugs was analysed using the tetramethyl-
benzidine method [30], and was normalised according to
plug weight and expressed as ng/mg plug.
Intravital microscopy (IVM)
Synovial capillaries in knee joints were monitored by
IVM as previously described [31]. Studies were per-
formed at the University of Rostock, Germany. CIA was
induced as described above in male DBA/1J mice. A
control group of mice received injections of CFA alone
followed by IFA alone 21 days later. Mice were anesthe-
tised with ketamine (90 mg/kg body weight) and xylacin
(6 mg/kg), and kept on a heating pad (37°C). After exci-
sion of the skin and soft tissue surrounding the knee
joint, the patella tendon was cut transversally and lifted
to expose the Hoffa’s fatty body. The tissue was super-
fused with 37°C saline and covered with a glass slide.
Following a 10-minute stabilisation period, in vivo
microscopy of the synovial tissue was performed. Mice
received an intravenous injection of fluorescein isothio-
cyanate (FITC)-labelled dextran (15 mg/kg body weight;
Sigma, Deisenhofen, Germany) for vascular contrast
enhancement. In vivo microscopy was performed using
a Zeiss microscope (Axiotech Vario 100HD; Carl Zeiss,
Oberkochen, Germany) equipped with a 100W mercury
lamp and filter sets for blue light epi-illumination (exci-
tation/emission wavelength: 450 to 490 nm/> 520 nm).
A 40-fold water immersion objective (total magnifica-
tion: 630) was used to randomly select three to five
non-overlapping regions of interest per tissue containing
capillaries. Microscopic images were recorded for offline
evaluation via a charge-coupled device video camera (FK
6990-IQ-S; Pieper, Schwerte, Germany). Quantitative
offline analysis was performed by means of a computer-
assisted image analysis system (CapImage v7.4; Dr.
Zeintl Software, Heidelberg, Germany). Functional capil-
lary density, defined as the total length of red blood
cell-perfused capillaries per observed area, as well as
capillary diameter were analysed.
Statistical analysis
Data were analysed using Graph-Pad Prism 5.01 (Graph-
Pad Software, San Diego, CA). Gene expression data were
analysed applying the Students t-test, Mann-Whitney or
one-way analysis of variance (ANOVA) as appropriate.
Clinical arthritis data were analysed by two-way ANOVA.
Histology data were analysed by the Mann-Whitney or
chi-square test for trend as appropriate. P-values ≤ 0.05
were considered significant.
Results
Synovial vascularisation in acute CIA
Immunohistochemistry for CD31 was performed to
assess the presence of microvessels in arthritic paws at
the peak of CIA (Figure 1A). Staining for CD31 revealed
occasional blood vessels with distinct lumen in paws
obtained from healthy mice (not immunised with CII),
whereas arthritic paws displayed marked vascularity espe-
cially in areas of dense cellular infiltration and in regions
of synovium invading the bone. A number of vessels pre-
sented with a distinct lumen while other vessels appeared
compressed. Although arthritic paw synovia showed
regions of high vascular density, non-vascularised regions
could also be identified.
Histology can help to detect synovial vessels, but it
does not provide information about their functionality.
We therefore applied intravital microscopy (IVM) to
compare the functional capillary density in knee joints
of healthy (not immunised with CII, n = 17) and
arthritic (n = 29) mice at different time points through-
out the disease course. The knee joint is the only joint
which can be assessed for IVM without inducing major
trauma [31]. Only mice with clinically evident knee joint
arthritis were included in our analysis. Diseased knee
joints presented with severe swelling of the soft tissue
around the patella tendon, indicating synovial inflamma-
tion and oedema. The functional capillary density (FCD)
was significantly decreased in arthritic tissue (P = 0.027,
Mann Whitney test), with an FCD of 320.30 ± 9.76 cm/
cm2 (mean ± standard error of the mean, SEM) in knee
synovia of healthy mice compared to an FCD of 286.70
± 8.23 cm/cm2 in arthritic mice (Figure 1B). The func-
tional capillary density correlated inversely with the clin-
ical score of analysed mice (Pearson correlation; P =
0.033, data not shown). The diameter of synovial capil-
laries was significantly (P = 0.030, Mann Whitney test)
enlarged in arthritic joints compared to healthy control
joints (Figure 1C; healthy 5.50 ± 0.08 µm versus arthritic
5.77 ± 0.07 µm; mean ± SEM). These data indicate that
the vascular turnover is increased, but a fraction of
Raatz et al. Arthritis Research & Therapy 2012, 14:R169
http://arthritis-research.com/content/14/4/R169

















































































Figure 1 Synovial neovascularisation in mice with acute collagen-induced arthritis (CIA). A) Histopathological features of haematoxylin
and eosin (H&E) or anti-CD31 stained serial paw sections from healthy and arthritic mice at the peak of CIA. Images show the metatarsal joints
(original magnification × 40). B) Functional capillary density and C) capillary diameter in knee joint synovial tissue of mice with established CIA
(n = 29) in comparison to age-matched healthy (n = 17) mice as revealed by intravital microscopy (IVM). The arthritic group included mice
analysed at different time points throughout the course of CIA. Data are expressed as mean ± SEM (Mann Whitney test, *P < 0.05).
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capillaries are functionally abnormal in the arthritic
synovial tissue during CIA.
Arthritic paw homogenates induce endothelial cell
migration in vitro
Since synovial tissue of arthritic paws presented with
increased vascularisation, as evident by abundant CD31
expression (Figure 1A), we tested whether angiogenic
activity could be detected in paw homogenates of
arthritic mice at the peak (day 8 following disease onset)
of CIA. We therefore investigated the migratory response
of HMEC-1 endothelial cells towards paw homogenates
using a chemotaxis assay. Figure 2 (A, B) illustrates that
homogenates of arthritic paws (n = 15) significantly
induced the migration of HMEC-1 when compared to
homogenates of healthy paws (n = 5) obtained from mice
immunised with CFA/IFA without CII (P = 0.003).
Arthritic paw homogenates elicited a similar migratory
response to that induced by hVEGF (migratory index
1.66 ± 0.14 and 1.77 ± 0.26, respectively), whereas healthy
paw homogenates displayed a slightly lower migratory
activity than PBS.
Arthritic paw homogenates induce angiogenesis in vivo
To investigate whether paw homogenates were able to eli-
cit an angiogenic response in vivo, Matrigel plug assays
were performed. For this purpose, Matrigel containing
paw homogenates at a concentration of 120 µg protein/ml
Matrigel was injected subcutaneously into the backs of
C57BL/6 mice. Each animal simultaneously received one
plug containing homogenate from a healthy paw and one
plug containing homogenate from an arthritic paw (or
murine FGF-2 as a positive control). Plugs were removed
7 days later. The degree of plug vascularisation was ana-
lysed by determining the haemoglobin content of the
implants. Plugs with arthritic tissue homogenates (n = 6)
(peak of CIA, day 8) contained significantly (P = 0.034)
more haemoglobin than plugs with healthy (n = 6) tissue
extracts (Figure 2C; healthy 20.98 ± 13.27 versus arthritic
1793 ± 723.6 ng haemoglobin/mg plug; mean ± SEM).
Temporal expression profile of angiogenesis-relevant
genes during CIA
In order to determine if the expression of genes regulat-
ing angiogenesis was altered during the course of CIA,
age-matched, male DBA/1 mice were immunised with
CII. Arthritic paws were collected on day 1 (onset), day 4,
day 8 (peak) and day 12 (declining phase) of CIA. To
account for possible adjuvant-induced expression
changes, one group of mice was immunised with CFA/
IFA alone without CII, while a further group of mice was
left untreated (naïve). For the Angiogenesis RT2-Profiler®
Array, a pool of RNA was prepared for each control and
time point, containing the same amount of RNA from
whole paws of different animals (n = 4). Expression levels
were analysed from six different groups: naïve mice, mice
immunised with CFA/IFA without CII (healthy), arthritic
animals on day 1, 4, 8 and 12 of CIA. The mRNA level of
target genes was normalised to the mean mRNA level of
four housekeeping genes (b-actin, Gapdh, Hsp-1, Hprt-1),
since their expression was stable between sample groups.
The expression of b-glucuronidase (Gusb) was increased
in arthritic samples and therefore excluded from the ana-
lyses. Indeed, it has been reported that the level of GUSB
is elevated in synovial fluids of RA patients [32]. The
immunisation with CFA/IFA alone without CII resulted
in slight alterations in the expression of genes for pro-
inflammatory cytokines (Il-6, Tnfa), chemokines (Cxcl5,
Cxcl1) and leptin (data not shown) when compared to
naïve animals. Therefore, all subsequent gene expression
in arthritic paws was compared using the gene expression
in paws of mice immunised with CFA/IFA without col-
lagen (healthy) as baseline.
The RT2-Profiler® Array profiles 84 angiogenesis-rele-
vant genes, of which 41 were identified as altered (fold
change ≤ -2 or ≥ 2) at least at one time point of CIA
(Table 2). Among these genes, 32 were up-regulated and 9
were down-regulated in arthritic paws compared to con-
trol paws. The majority of up-regulated genes reached
their maximum expression on day 8 of arthritis, at which
time symptoms of arthritis peaked, with gene expression
levels gradually decreasing again on day 12, when the dis-
ease started to resolve, indicating a role for those genes in
disease progression.
As might be predicted, a substantial fold increase could
be observed for genes related to inflammation (for exam-
ple, Cxcl5, Cxcl1, Il-6, Il-1), cell adhesion (for example,
integrin b3, cadherin 5) and proteolysis (for example,
Mmp-9, Mmp-19). Up-regulated angiogenic growth fac-
tors included Hgf, insulin-like growth factor (Igf)-1, mid-
kine (Mdk) and angiopoietin (Ang)-1, whereas leptin and
epidermal growth factor (Egf) were decreased in arthritic
paws. No difference for total Vegf/a transcript levels could
be detected between arthritic and control tissue (not
shown), whereas its receptors Flk-1 and neuropilin (Nrp)-2
were increased in arthritic mouse paws. Interestingly, the
expression levels of genes that play a role in inhibiting
angiogenesis were also increased during CIA (for example,
thrombospondins, endostatin).
Gene-specific real-time RT-PCR for selected genes
using samples from individual animals was performed to
validate the observed trends in the array. For this pur-
pose, samples were obtained from arthritic animals on
day 1 (onset, n = 5), day 4 (n = 6), day 8 (n = 7) and day
12 (n = 6) of CIA, as well as from mice immunised with
CFA/IFA without CII (healthy, n = 6). To investigate pos-
sible alterations before the onset of clinical arthritis, we
included a group of mice that were sacrificed 14 days
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Figure 2 Induction of angiogenic responses by joint homogenates from mice with collagen-induced arthritis (CIA). A) Arthritic joint
homogenates significantly induced the migration of endothelial cells (HMEC-1) in vitro. Representative photographs of migrated HMEC-1 in
response to different stimuli (original magnification × 200). B) Graph illustrates HMEC-1 migration in response to paw homogenates (100 µg
protein/ml) of healthy (n = 5) or arthritic (n = 15) mice in comparison to 20 ng/ml recombinant human VEGF (hVEGF) (n = 6). The migration
index was calculated by dividing the number of migrated cells in the presence of stimuli by the number of migrated cells in the presence of
PBS (set as 1, dashed line). Results were expressed as mean ± SEM and analysed by unpaired t-test (**P < 0.01). C) Homogenates of arthritic
paws induce angiogenesis in vivo. Representative images of Matrigel plugs comparing healthy (1, 3) with arthritic (2, 4) paw homogenate-
containing plugs. Graph demonstrates the haemoglobin content of isolated Matrigel plugs. Recombinant murine fibroblast growth factor (FGF)-2
(mFGF-2, 30 ng/ml) was used as a positive control. Data expressed as mean ± SEM (healthy, n = 6; arthritic,n = 6; FGF-2, n = 3) and analysed by
unpaired t-test: *P < 0.05.
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Table 2 Angiogenesis-related genes altered during the course of acute CIA

















Growth factors and receptors
Ang-1 NM_009640 Angiopoietin 1 1.3 1.8 2.7 0,004 1.5
Edg1 NM_007901 Endothelial differentiation sphingolipid G-protein-
coupled receptor 1
1.8 2.4 0,001 3.3 0,002 2.4 0,005
Egf NM_010113 Epidermal growth factor -1.4 -2.9 0,013 -3.7 0,005 -2.9 0,005
Ereg NM_007950 Epiregulin -1.4 -2.1 0,001 -2.3 0,002 -1.8
Fgf-1 NM_010197 Fibroblast growth factor 1 -1.3 -2.3 0,004 -1.7 -1.1
Flk-1 NM_010612 Fetal liver kinase 1.3 2.2 0,011 3.0 0,006 1.9
Hgf NM_010427 Hepatocyte growth factor 2.2 0,006 4.6 0,001 6.0 0,001 3.9 0,002
Igf-1 NM_010512 Insulin-like growth factor 1 1.4 2.4 0,000 4.1 0,001 2.4 0,000
Lep NM_008493 Leptin -2.5 0,007 -5.8 0,002 -6.8 0,002 -3.9 0,015
Mdk NM_010784 Midkine 1.5 2.4 0,008 7.5 0,002 5.3 0,003
Nrp-2 NM_010939 Neuropilin 2 1.4 2.0 0,009 2.4 0,015 2.2 0,011
Tgfb1 NM_011577 Transforming growth factor, beta 1 1.6 2.1 0,009 2.3 0,005 1.8
Tgfb2 NM_009367 Transforming growth factor, beta 2 -1.4 -2.0 0,021 -1.3 1.1
Tgfbr1 NM_009370 Transforming growth factor, beta receptor I 1.5 1.6 2.0 0,003 1.5
Proteases and inhibitors
Mmp-2 NM_008610 Matrix metallopeptidase 2 1.7 2.6 0,001 4.1 0,000 3.0 0,001
Mmp-9 NM_013599 Matrix metallopeptidase 9 3.4 0,002 16.2 0,001 20.2 0,001 12.7 0,001
Mmp-
19
NM_021412 Matrix metallopeptidase 19 3.6 0,001 4.6 0,002 5.2 0,000 3.8 0,003
Timp-1 NM_011593 Tissue inhibitor of metalloproteinase 1 17.1 0,009 34.0 0,001 24.4 0,001 11.6 0,001
Timp-2 NM_011594 Tissue inhibitor of metalloproteinase 2 1.2 1.4 2.4 0,001 2.1 0,001
Adhesion molecules
Cdh5 NM_009868 Cadherin 5 1.6 3.0 0,003 3.5 0,002 2.3 0,017
Eng NM_007932 Endoglin 1.6 1.9 2.6 0,007 1.9
Itgb3 NM_016780 Integrin beta 3 1.9 5.9 0,001 6.1 0,001 3.4 0,001
Pecam1 NM_008816 Platelet/endothelial cell adhesion molecule 1 1.7 1.7 2.1 0,012 1.8
Stab1 NM_138672 Stabilin 1 2.6 0,000 4.0 0,001 3.3 0,001 2.0 0,002
Transcription factors
Efnb2 NM_010111 Ephrin B2 -2.0 -2.5 0,001 -1.7 -1.1
Hif-1a NM_010431 Hypoxia inducible factor 1, alpha subunit 1.5 2.6 0,001 3.8 0,000 1.6
Tbx1 NM_011532 T-box 1 -1.7 -3.3 0,003 -3.3 0,011 -2.0 0,013
Tnfaip2 NM_009396 Tumor necrosis factor, alpha-induced protein 2 2.0 0,002 2.6 0,004 2.6 0,001 2.0 0,001
Anti-angiogenic factors
Tsp-1 NM_011580 Thrombospondin 1 1.8 1.9 2.8 0,000 2.0 0,006
Tsp-2 NM_011581 Thrombospondin 2 1.3 2.2 0,003 2.9 0,001 2.0 0,002
Col4a3 NM_009929 Procollagen, type IV, alpha 3/tumstatin 1 -2.0 0,015 -2.0 0,011 -1.3
Col18a1 NM_007734 Procollagen, type XVIII, alpha 1/endostatin 1.1 1.7 2.0 0,012 2.0 0,015
Cytokinesand chemokines
Il-1b NM_008361 Interleukin 1 beta 34.1 0,000 48.2 0,000 60.0 0,000 16.2 0,000
Il-6 NM_031168 Interleukin 6 183.7 0,000 190.4 0,000 164.7 0,000 30.3 0,001
Tnfa NM_013693 Tumor necrosis factor 2.2 0,014 2.2 0,009 3.7 0,010 2.2 0,018
Ccl2 NM_011333 Chemokine (C-C motif) ligand 2/MCP1/HC11 15.0 0,000 11.0 0,001 10.0 0,000 3.0 0,001
Cxcl1 NM_008176 Chemokine (C-X-C motif) ligand 1/Gro1 19.2 0,003 35.7 0,001 21.0 0,001 7.0 0,019
Cxcl2 NM_009140 Chemokine (C-X-C motif) ligand 2/Grob 8.7 0,001 13.4 0,001 15.2 0,001 6.1 0,001
Cxcl5 NM_009141 Chemokine (C-X-C motif) ligand 5/ENA-78 126.3 0,002 378.4 0,001 345.8 0,001 70.3 0,003
Ccl11 NM_011330 Small chemokine (C-C motif) ligand 11/eotaxin 1.1 -2.0 0,003 -2.0 0,019 1.2
Csf3 NM_009971 Colony stimulating factor 3 (granulocyte)/G-CSF 86.9 0,016 69.7 0,017 48.9 0,020 20.3 0,034
Angiogenesis RT2-Profiler PCR arrays (APM-024; SuperArray Bioscience, Frederick, MD) were performed using cDNA from paws of CIA mice at different time points
post-arthritis onset. For each time point, RNA from four animals was pooled and analysed in duplicate. Data are expressed as fold change relative to the
expression in paws from healthy mice after normalisation to four housekeeping genes. The table lists genes that exhibit at least a two-fold difference in
expression at one or more time-points in arthritic tissue when compared to control tissue. Data were analysed by paired t-test.
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after immunisation with collagen but without macro-
scopic signs of CIA (pre-arthritic, n = 4). The expression
of target genes was normalised to Arp expression, which
displayed expression stability among the different condi-
tions (healthy, pre-arthritic, arthritic). Figure 3 illustrates
the kinetics of mRNA expression for Hgf, Igf-1, Mdk,
Hgf









































































































































































































Figure 3 mRNA expression of angiogenesis-modulating factors during the course of collagen-induced arthritis (CIA). Mice at different
stages of disease were sacrificed and whole paws processed for mRNA quantification by real-time RT-PCR. Data are presented as fold change in
mRNA level relative to the mean expression in six age-matched healthy controls (dotted line) after normalisation to the acidic ribosomal
phosphoprotein P0 (Arp) gene. Data are from individual mice (n = 5 to 7), bars indicate the median mRNA level of the different groups.
Statistical analysis of data was performed using one-way ANOVA with Dunn’s post hoc test for multiple comparisons, compared against pre-
arthritic mice (*P < 0.05, **P < 0.01, ***P < 0.001).
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Tnfa, Il-1b and Il-6 in arthritic tissue. Their temporal
expression pattern reflected disease activity, with most
prominent changes occurring at the peak phases of CIA,
with mean clinical scores ± SEM for the analysed paw of
1 ± 0.00 on day 1, 1.75 ± 0.25 on day 4, and 2.14 ± 0.37
on day 8. A significant increase in transcript levels could
be observed on day 8 for all genes, with mRNA levels
gradually decreasing on day 12 (mean clinical score ±
SEM of the analysed paws 1.67 ± 0.38), which is consis-
tent with the array results. We have previously reported
that expression of Ang-1, Ang-2, tyrosine kinase with
immunoglobulin-like and EGF-like domains (Tie)-1 and
Tie-2 increases as arthritis progressed, peaking on day 8
of disease [33]. Of these, Ang-2 and Tie-2 showed modest
changes (below 2-fold) on the array, whereas Ang-1
increased 2.7-fold on day 8 (Table 2).
Unexpectedly, the array identified the expression of
total Vegf/a mRNA as unchanged in arthritic tissue,
despite strong evidence supporting a role for VEGF in
both animal models of disease [21-23] and human RA
[9,11,15]. Therefore, we examined the expression of dif-
ferent VEGF isoforms using samples from individual ani-
mals by gene-specific RT-PCR (Figure 4). Transcript
levels for Vegf120 and Vegf164 were significantly elevated
on day 8 of arthritis compared to pre-arthritic animals.
However, the changes were only minor (below 2-fold).
The expression of Vegf188 did not change during the
course of CIA (data not shown). No significant change in
the mRNA level for placental growth factor (Plgf) could
be observed at the analysed time points. For the regula-
tion of angiogenesis, not only the expression of growth
factors is important, but also the expression of the
respective receptors. Maximal induction of Flt-1 and
Flk-1 transcript levels was observed on day 8 (2.7- and
4.2-fold respectively), whereas the level for Nrp-1, which
can act as an enhancer for VEGF receptor signalling, had
its peak expression already on day 4 of CIA. This con-
firms array results, although changes identified by the
array for Flt-1 and Nrp-1 mRNA were below 2-fold.
Anti-NRP1B inhibits HMEC-1 migration induced by
arthritic paw homogenates
Our gene expression analysis revealed that the mRNA
level for Nrp-1 is elevated in arthritic tissue of mice with
CIA. As opposed to the other VEGF receptors, it reached
its maximum expression already on day 4 of arthritis. To
further analyse its role in arthritis-induced angiogenesis,
we investigated whether NRP-1 function is required for
the induction of endothelial cell migration by arthritic paw
homogenates applying a neutralising antibody that specifi-
cally blocks the binding of VEGF121 and VEGF164 to
NRP-1 [28,34]. Therefore, HMEC-1 were added together
with either anti-NRP1B or PBS into the upper chamber of
the cell culture inserts, while paw homogenates (100 µg
protein/ml) were added into the bottom cell culture well
to promote endothelial cell migration. Blocking the VEGF-
binding domain of the NRP-1 receptor on endothelial cells
significantly reduced endothelial cell migration towards
arthritic paw homogenates (Figure 5). However, the migra-
tory response was still greater than induced by healthy
paw homogenates, which seem to inhibit endothelial
migration, as the number of migrated cells was lower than
that induced by PBS alone, which is consistent with data
presented in Figure 4B.
Treatment with anti-NRP1B significantly reduces disease
severity and joint destruction in collagen-induced arthritis
Since anti-NRP1B reduced the migratory response of
endothelial cells induced by arthritic paw homogenates,
we aimed to further elucidate the role for NRP-1 in disease
progression in arthritic animals. In a pilot study, a small
cohort of mice (n = 5 per group) received intraperitoneal
injections of 200 µg anti-NRP1B, 200 µg isotype matched
control antibody or an equivalent volume of PBS on day 1
(onset - when first clinical signs of CIA were evident), and
additionally on day 4 and day 7 of arthritis. Mice were
scored every other day until day 8 of arthritis. Treatment
with anti-NRP1B resulted in a marked attenuation of CIA,
with the clinical score significantly lower when compared
to both untreated mice (P < 0.01, two-way ANOVA) and
isotype control antibody-treated mice (P < 0.01), thus rul-
ing out unspecific effects (Figure 6A).
Subsequently, a larger cohort of mice (n = 10 per group)
received intraperitoneal injections of 200 µg anti-NRP1B
or an equivalent volume of PBS on day 1 (onset - when
first clinical signs of CIA were evident), and additionally
on day 4 and day 7 of arthritis. Over the course of ten
days, mice were macroscopically monitored and assigned a
clinical score. Additionally, paw swelling of hind paws was
measured. In order to normalise the results, data were
calculated as change relative to day 1. Treatment with
anti-NRP1B resulted in a marked attenuation of CIA. As
Figure 6B demonstrates, the administration of the anti-
NRP1B antibody significantly reduced the severity of paw
inflammation indicated by the change in clinical score
compared to PBS administration (P < 0.001). For instance,
the change in clinical score on day 10 of arthritis after
anti-NRP1B treatment was 1.85 ± 0.67 (mean ± SEM)
compared to 4.8 ± 0.79 for PBS-treated mice. The increase
in hind paw swelling following anti-NRP1B treatment was
also significantly lower when compared to mice receiving
only PBS treatment (P < 0.001). To illustrate, on day
10 the change in paw swelling in anti-NRP1B-treated mice
was 0.07 ± 0.05 mm (mean ± SEM) and 0.53 ± 0.08 mm
in PBS-treated mice.
To determine whether anti-NRP1B antibody amelio-
rated joint destruction, hind paws were harvested on day
10 and histologically examined. Joints of mice treated
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with anti-NRP1B exhibited fewer infiltrating inflamma-
tory cells in the synovium as well as reduced cartilage
erosion and bone degradation when compared to those
of mice treated with PBS alone (Figure 6C). The mean
histological score was significantly lower than after PBS
administration (P = 0.041). Overall, anti-NRP1B-treated
mice exhibited a significant improvement in joint histol-
ogy (Table 3). The percentages of mice exhibiting normal
Vegf120










































































































































































































Figure 4 mRNA expression of the VEGF/VEGF receptor family during the course of CIA. Mice at different stages of disease were sacrificed
and whole paws processed for mRNA quantification by real-time RT-PCR. Data are presented as fold change in mRNA level relative to the mean
expression in six age-matched healthy controls (dotted line) after normalisation to the acidic ribosomal phosphoprotein P0 (Arp) gene. Data are
from individual mice (n =5 to 7), bars indicate the median mRNA level of the different groups. Statistical analysis of data was performed using
one-way ANOVA with Dunn’s post hoc test for multiple comparisons, compared against pre-arthritic mice (*P < 0.05, **P < 0.01, ***P < 0.001).
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joint histology or only mild synovitis were 42.1% and
17.5%, respectively, compared to 20.7% and 5.2% in PBS-
treated mice. Taken together, these results demonstrate
that blocking VEGF binding to NRP-1 reduces clinical
and histopathological severity of CIA.
Discussion
In RA and the relevant mouse CIA model, angiogenesis is
considered to promote and exacerbate synovial inflamma-
tion and cartilage/bone erosion by facilitating the recruit-
ment of inflammatory cells, and by providing oxygen and
nutrients to the hyperplasic tissue [2,3]. Although the
importance of angiogenesis in the pathology of arthritis is
well recognised, there is little information about the func-
tion of the blood vasculature. In the present study, we
demonstrated for the first time that despite an increased
vascular turnover, the functional capillary density is
decreased in synovial tissue of arthritic joints during CIA.
This reduction will further exacerbate the insufficient sup-
ply of nutrients and oxygen to the synovium, which could
explain the observed hypoxic environment found in
arthritic joints of mice [19]. Additionally, we observed an
active pro-angiogenic microenvironment in arthritic paws,
which was also reflected in an increased number of CD31-
positive vessels and endothelial cells. These findings sug-
gest that an imbalance of molecular factors regulating ves-
sel formation and maturation contributes to abnormal
synovial neovessel function.
To further elucidate the molecular mechanisms underly-
ing this dysregulated synovial angiogenesis and to identify
potential targets for therapeutic intervention, we charac-
terised the expression of angiogenesis-related genes during
the progression of murine CIA applying quantitative real-
time RT-PCR. Our results show that the expression of
hypoxia inducible factor 1alpha (HIF-1a), a key mediator
of hypoxic responses, is elevated during the course of CIA
in arthritic paws compared to healthy paws. In RA, HIF-
1a induces the transcription of matrix metalloproteinases
(MMPs) and pro-angiogenic growth factors, including
VEGF, thus activating the angiogenic cascade as well as
matrix degradation [35]. Not surprisingly, the most nota-
ble alterations occurred in the expression of genes
involved in inflammation (for example, pro-inflammatory
cytokines Il-1b, Il-6, Tnfa) and tissue remodelling (for
example, Mmp-2, Mmp-9, Mmp-19). TNFa and IL-1b, as
well as playing roles in the inflammatory component of
RA, modulate synovial angiogenesis by inducing the pro-
duction of angiogenic mediators like VEGF, ANG-1,
ANG-2 and TIE-2 by RA synoviocytes [9,10,20]. MMPs
participate in angiogenesis by degrading and remodelling
the extracellular matrix and basement membranes, allow-
ing activated endothelial cells to proliferate and migrate,
as well as releasing extracellular matrix-bound growth fac-
tors such as FGF-2, VEGF or IGF-1 [36].
Our results further indicate that a hypoxic and pro-
inflammatory microenvironment induces the transcrip-
tional activation of angiogenic growth factors in arthritic
joints of CIA mice, including midkine and Hgf. Elevated
levels of midkine have been detected in the serum and
synovial fluid of RA patients [37,38], and HGF levels
within the arthritic joint correlate with disease activity
[39] and synovial microvessel density [13]. On the other
hand, EGF, which has been reported as elevated in RA
synovial fluids [40], was down-regulated during CIA.
Further, we detected a significant decrease of leptin
mRNA levels in arthritic paws, which is consistent with
published gene expression data in murine CIA [41].
Leptin, apart from the regulation of food intake, has been
implicated in the regulation of immune responses and
angiogenesis [42].
Although the mRNA levels of VEGF isoforms and Plgf
were only modestly (below 2-fold) altered during CIA,
the VEGF signalling pathway was clearly affected, since
the expression of its tyrosine kinase receptors Flt-1 and
Flk-1 as well as its co-receptors Nrp-1 and Nrp-2 was sig-
nificantly increased during CIA. This relatively small
increase in Vegf expression was unexpected, especially in
view of data showing high VEGF secretion by mouse CIA
synovial membrane cells [23] or the effectiveness of anti-
VEGF treatment in experimental arthritis [21-23]. How-
ever, the difference in VEGF mRNA levels [43] or protein

















Figure 5 Blocking neutropilin (NRP)-1 inhibits human
microvascular endothelial cells (HMEC)-1 migration induced by
arthritic paw homogenates. The ability of anti-NRP1B antibody to
inhibit the migration of HMEC-1 in response to paw homogenates
was evaluated using a chemotaxis assay. Cells were seeded in
presence of anti-NRP1B (10 µg/ml) or PBS into the upper chamber
and allowed to migrate towards paw homogenates (100 µg
protein/ml) in the lower chamber. PBS as stimulant was used as a
negative control (set as 1, dashed line). Data expressed as mean ±
SEM (healthy, n = 3; arthritic, n = 6). Data were analysed using two-
way ANOVA: ***P < 0.001.
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Figure 6 Treatment with phage-derived monoclonal antibody against neuropilin-1 (anti-NRP1B) reduces disease severity in collagen-
induced arthritis (CIA). A) Isotype-matched control antibody has no effect on disease progression in CIA mice. Starting at the onset of clinically
evident arthritis, mice were randomised into three groups (n = 5/group) and treated intraperitoneally with 200 µg anti-NRP1B antibody, 200 µg
isotype-matched control antibody or PBS on day 1, day 4 and day 7 of CIA. The clinical score was recorded every other day and presented as
change from day 1. B) Effect of anti-NRP1B on the clinical progression of arthritis. Starting on the first day of clinically evident arthritis, mice
received 200 µg anti-NRP1B antibody or PBS intraperitoneally on day 1, day 4 and day 7 of CIA. The clinical score and paw swelling were
recorded daily and presented as change from day 1. Data are expressed as mean ± SEM (n = 10/group) and analysed by two-way ANOVA (PBS
versus anti-NRP1B; ***P < 0.001). Results are representative of three independent experiments. C) Paws from anti-NRP1B-treated mice (b) displayed
significantly reduced articular inflammation and destruction compared to those from PBS-treated mice (a). After treatment, hind paws were
collected, fixed, decalcified, and haematoxylin/eosin sections prepared. Histological appearance was scored for the degree of bone erosion,
synovial hyperplasia, and cellular infiltration. Shown are representative metatarsal joint sections from PBS-treated and anti-NRP1B-treated mice
(original magnification × 40). The histological changes differed significantly between the two treatment groups (Mann Whitney test, *P < 0.05).
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also reported to be not more than 1.5- to 1.6-fold. Taken
together, these findings indicate that in the CIA model,
VEGF expression does not change markedly, but seems
nonetheless sufficient to induce pathological angiogen-
esis, and suggest that VEGF-mediated angiogenesis is lar-
gely modulated through an increase in surface expression
of VEGF receptors on target cells, thereby increasing
their responsiveness towards the angiogenic stimuli.
Another pathway involved in vessel formation and
maturation is the ANG/TIE system. In a previous study
we have shown that the expression of Ang-1, Ang-2, Tie-1
and Tie-2 mRNA is significantly higher in arthritic tissue
of CIA mice, and that the application of a splice variant of
TIE-1 ameliorates disease severity, reduces synovial vascu-
larisation and bone destruction [33]. Our angiogenesis
array identified Ang-1 as up-regulated by more than
2-fold, whereas Ang-2 was increased by only 1.6-fold on
day 8 of CIA. Co-expression of angiopoietins and their
receptors is observed in rheumatoid synovial tissue
[10,12]. ANG-1 signalling through TIE-2 maintains vessel
integrity through the recruitment of pericytes, while
ANG-2 blocks ANG-1/TIE-2 signalling, loosening the vas-
cular structure and exposing the endothelium to inducers
of angiogenesis such as VEGF [45]. In addition to
increased transcription of angiogenic factors, the mRNA
levels of some anti-angiogenic molecules (thrombospon-
dins, endostatin) were also elevated, although their expres-
sion might not be sufficient enough to counteract the
angiogenic response, since arthritic paw homogenates
were able to induce endothelial cell chemotaxis in vitro as
well as angiogenesis in vivo.
Our results reveal the existence of angiogenesis-related
gene expression signatures in arthritic tissue and clearly
indicate an active pro-angiogenic microenvironment in
arthritic paws, which was also reflected in the increased
number of CD31 positive vessels and endothelial cells.
However, although the vascular turnover was increased
within the inflamed synovium during CIA, the functional
capillary density in arthritic synovial tissue was decreased.
A previous IVM study revealed a trend towards a reduced
functional capillary density in the synovium of pre-
arthritic knee joints already before the onset of CIA [26].
Further, the diameter of the synovial capillaries in pre-
arthritic mice was enlarged. These findings are in agree-
ment with our observations in arthritic mice. It may seem
counterintuitive that the arthritic synovium exhibits a
lower functional microvessel density than healthy syno-
vium, despite exhibiting a pro-angiogenic microenviron-
ment and histologically an increased vascularisation. The
human RA synovium contains regions of ongoing angio-
genesis, indicated by endothelial cell proliferation, and
regions of vascular regression, evident by markers of DNA
damage and endothelial cell death [5]. However, angiogen-
esis not only depends on endothelial cell invasion and pro-
liferation, but also requires coverage of vascular sprouts by
peri-endothelial cells for vessel stabilization. Similar to
tumour vasculature, a significant fraction of the synovial
vasculature in arthritic joints of RA patients has not yet
recruited peri-endothelial cells, which are essential for
functional vascular patterning, diameter regulation, and
vessel stabilisation [46,47].The vascular network is thus
dysfunctional in RA, and the presence of unstable vessels
is associated with hypoxia, incomplete endothelial cell-
pericyte interactions, increased DNA damage, disease pro-
gression and increased lymphocyte infiltration [46,47].
Over-expression of angiogenic factors and receptors, as
demonstrated in our present study, is likely to drive and
maintain angiogenesis, as evidenced by the pro-angiogenic
activities of arthritic paw extracts, but if uncontrolled,
might actually promote further hypoxia and hence angio-
genesis, while not allowing vessel maturation. For example,
VEGF-mediated vessel formation has been associated with
an imbalance between endothelial cell tube formation and
the parallel development of pericytes [48]. Although the
maturation status of vessels within the CIA synovium
needs further investigation, vessel immaturity as well as an
increased endothelial cell turnover could be an important
factor contributing to the hypoxic environment found in
the arthritic synovium of mice [19] and humans [6,49],
thereby aggravating synovial inflammation. Thus, despite
apparent high vascularity, the arthritic synovium remains
a rather inhospitable environment, with marked hypoxia
and acidosis [6,50], suggesting that blood flow is impaired
and insufficient to meet the metabolic demand of inflamed
synovial tissue. It might therefore be speculated that just
like in cancer, vessel normalisation as a therapeutic inter-
vention could improve the efficacy of immunotherapy in
RA.
Using IVM, we detected a significant increase in the dia-
meter of synovial capillaries in arthritic knee synovium.
Vessel dilation probably indicates ongoing angiogenesis,
since it is one of the first steps preceding vessel sprouting.
Capillaries might be in a plastic state, responsive to
Table 3 Effect of anti-NRP1B treatment on joint
inflammation and destruction in mice with collagen-
induced arthritis
Joint findings, %
Treatment Normal Mild Moderate Severe P†
PBS 20.7 5.2 32.7 41.4
anti-NRP1B 42.1 17.5 22.9 17.5 0.0021
Values are the percentage of joints with normal appearance or exhibiting
inflammation and cartilage/bone degradation graded as mild, moderate, or
severe, as assessed by haematoxylin and eosin. The numbers of joints assessed
were as follows: 57 in the phage-derived monoclonal antibody against
neuropilin-1 (anti-NRP1B)-treated group and 58 in the PBS-treated group.
† The absolute numbers of mice exhibiting normal, mild, moderate, and
severe arthritis changes were compared, and significance versus untreated
mice was analysed by chi-square test for trend.
Raatz et al. Arthritis Research & Therapy 2012, 14:R169
http://arthritis-research.com/content/14/4/R169
Page 15 of 18
pro-angiogenic stimuli (for example, VEGF), resulting in
increased capillary diameter, remodelling and sprouting of
new capillaries. This finding might also suggest that during
CIA, the synovium tries to adapt to hypoxia by both
angiogenesis and dilation of microvessels. However,
increased permeability of capillaries allows the escape of
plasma and plasma proteins in addition to the accumula-
tion of leukocytes in the synovium, exacerbating joint
inflammation.
The requirement of several angiogenic growth factors
for synovial angiogenesis and inflammation during CIA
has been shown previously, for example, by neutralising
VEGF function [21-23], depletion of midkine [37], or by
blocking angiopoietin signalling [33]. Our gene expres-
sion results suggest that VEGF-mediated angiogenesis
and inflammation during CIA is largely modulated
through increased expression of VEGF receptors and
co-receptors. NRP-1 not only modulates the function of
VEGF during angiogenesis by enhancing the binding of
VEGF165 isoform to VEGF-R2 [51], but also interacts
directly with VEGF121 [34] and other heparin-binding
growth factors, such as HGF, VEGF/B or PLGF [52]. In
the rheumatoid synovium, NRP-1 expression can be
found on synoviocytes, infiltrating leukocytes and on the
endothelium [17,53] and concomitant expression of
VEGF165, KDR, and NRP-1 is associated with a high
vascular density and increased inflammation [17]. These
observations, together with our findings showing
increased Nrp-1 expression during CIA, suggested that
blocking NRP-1 function may affect disease progression
by directly reducing synovial angiogenesis and leukocyte
infiltration. We applied a monoclonal antibody that tar-
gets the VEGF binding site on NRP-1 without interfer-
ing with its semaphorin signalling, and which has been
shown to reduce neovascularisation in tumour models
[28]. Our study revealed that anti-NRP1B is able to inhi-
bit endothelial cell migration induced by arthritic paw
extracts, confirming that arthritic tissue contains factors
that signal through NRP-1. Treatment with anti-NRP1B
significantly attenuated the progression of CIA as
assessed by paw swelling and clinical score. Importantly,
histological examination of arthritic hind paws demon-
strated that this clinical improvement was associated
with a reduction in synovial inflammation, pannus for-
mation, as well as destruction of cartilage and bone,
supporting the concept of a key role for this ligand-
receptor interaction in the pathogenesis of arthritis. The
role of NRP-1 in experimental arthritis has been studied
before [54]. The prophylactic administration of an anti-
NRP-1 peptide diminished disease severity in mouse
CIA. Although prophylactic studies offer valuable insight
into the molecular mechanisms underlying a disease,
care must be taken in translating such results into
potential therapeutic application. In contrast, our study
employed a therapeutic approach, in which only mice
with clinically evident arthritis received anti-NRP1B. Our
data indicate that NRP-1 signalling is required for the
maintenance and progression of established inflamma-
tory arthritis. However, further investigations are neces-
sary to elucidate the exact mechanism by which anti-
NRP1B therapy improves inflammatory arthritis.
Conclusions
While a number of gene expression studies in CIA have
been described, the present study was the first to focus on
genes associated with angiogenesis, which is a key feature
of RA. Our data are compatible with existing theories of
angiogenesis in RA, and suggest that synovial angiogenesis
results in the formation of dysfunctional vessels primarily
caused by an imbalance of pro- and anti-angiogenic fac-
tors. Our results confirm NRP-1 as a key player in the
pathogenesis of CIA, and support the VEGF/VEGF recep-
tor pathway as a potential therapeutic target in RA.
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